Genetic prodrug activation therapy

被引:26
|
作者
Rigg, A
Sikora, K
机构
[1] ICRF Molecular Oncology Unit, Imperial College of Medicine, Hammersmith Hospital, London W12 0NN, Du Cane Road
来源
MOLECULAR MEDICINE TODAY | 1997年 / 3卷 / 08期
关键词
D O I
10.1016/S1357-4310(97)01082-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Genetic prodrug activation therapy shows promise as a therapeutic option for the treatment of cancer as well as a variety of other diseases. it involves the insertion of a gene encoding a drug-metabolizing enzyme into cells and the systemic administration of a prodrug. The prodrug is converted to a cytotoxic agent by the action of the expressed enzyme. To ensure that the enzyme is only expressed in the targeted subset of cells, the transcriptional apparatus of a gene that is unique to this subset is used to regulate the gene encoding the drug-metabolizing enzyme. As with all types of gene therapy, one of the major obstacles to successful clinical treatment is the development of safe and effective gene delivery systems.
引用
收藏
页码:359 / 366
页数:8
相关论文
共 50 条
  • [1] Genetic prodrug activation therapy
    Martin, LA
    Vile, R
    Lemoine, NR
    Sikora, K
    Pandha, HS
    LANCET, 1997, 350 (9094): : 1793 - 1794
  • [2] Genetic prodrug activation therapy for pancreatic cancer
    Rigg, AS
    Lemoine, NR
    CELL AND MOLECULAR BIOLOGY OF PANCREATIC CARCINOMA: RECENT DEVELOPMENTS IN RESEARCH AND EXPERIMENTAL THERAPY, 1999, 880 : 319 - 325
  • [3] Genetic prodrug activation therapy for breast cancer.
    Pandha, HS
    BRITISH JOURNAL OF CANCER, 1999, 80 : 5 - 5
  • [4] The role of adenoviral vectors in genetic prodrug activation therapy in prostate cancer
    Eaton J.D.
    Clarke I.A.
    Pandha H.
    Dalgleish A.G.
    Kirby R.S.
    Prostate Cancer and Prostatic Diseases, 2000, 3 (Suppl 1) : S10 - S10
  • [5] Cell death associated with genetic prodrug activation therapy of colorectal cancer
    Todryk, S
    Melcher, A
    Bottley, G
    Gough, M
    Vile, R
    CANCER LETTERS, 2001, 174 (01) : 25 - 33
  • [7] Prodrug activation enzymes in cancer gene therapy
    Aghi, M
    Hochberg, F
    Breakefield, XO
    JOURNAL OF GENE MEDICINE, 2000, 2 (03): : 148 - 164
  • [8] Genetic prodrug activating therapy (GPAT) for cancer
    Sikora, K
    CANCER GENE THERAPY, 1997, 4 (01) : 69 - 69
  • [10] Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment
    Ma, Jie
    Waxman, David J.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (11) : 2879 - 2890